SCHEMBL9924052

SCHEMBL9924052

Cc1ccn2c(C)c(NC(=O)OC(C)(C)C)nc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.45
ALDH1A1 P00352 5/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
GAA P10253 4/20 0.39
PKM P14618 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
GFER P55789 1/20 0.38
BRD9 Q9H8M2 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
LCK P06239 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15631816 0.85 RXFP1 (0.41) KDM4EALDH1A1SMN1; SMN2HSD17B10BRD9
SCHEMBL9923873 0.83 ALDH1A1 (0.48) KDM4EALDH1A1SMN1; SMN2HSD17B10GAA
SCHEMBL22519304 0.83 KDM4E (0.42) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL9923990 0.81 KDM4E (0.44) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL9924039 0.76 ALDH1A1 (0.44) KDM4EALDH1A1SMN1; SMN2GAALMNA
SCHEMBL15631803 0.76 CYP11B1 (0.44) KDM4EALDH1A1SMN1; SMN2RAB9ACYP11B1
SCHEMBL9923891 0.74 SMN1; SMN2 (0.42) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL28842843 0.74 KDM4E (0.45) KDM4EALDH1A1SMN1; SMN2HSD17B10GAA
SCHEMBL9942081 0.74 MCHR1 (0.41) LMNA
SCHEMBL15690014 0.72 BRD9 (0.38) BRD9LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 KDM4E 3480/4885ALDH1A1 2230/4885SMN1; SMN2 442/4885
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 KDM4E 3480/4885ALDH1A1 2230/4885SMN1; SMN2 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.